fda warning letters to compounding pharmacies bpc 157 The U.S. Food and Drug Administration is moving toward allowing to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Beyond the Headlines: FDA Warning
Description
it raised a $53M Series A led by Andreessen Horowitz's Bio + Health practice in 2024 and a $298M Series B in November 2025 a signal of how much capital believes in measurement-first health.20,21 Superpower (founded 2023, Los Angeles) competes on price and software, offering 100+ biomarkers near $199/year with stronger AI tooling, a care team, and prescription access.21,22 Lifeforce takes the clinician-led route quarterly testing, physician interpretation, and prescription pathways aimed squarely at midlife performance and hormonal optimization.21 The category matured enough to produce its first major lawsuit: in January 2026, Function Health sued Superpower over allegedly deceptive advertising, a dispute that turned, revealingly, on the question of what even counts as a "biomarker."20 The strategic point for a reader evaluating cognitive peptides: these companies have solved the measurement half of the equation and are racing on price and panel size

Thats because hCG can act similarly to luteinizing hormone (LH), a chemical produced by the pituitary gland that stimulates ovulation

You'll inject subcutaneously anywhere on your body since TB-500 doesn't require site-specific targeting
Reconstitute with bacteriostatic water under sterile conditions prior to use
